Patents by Inventor Göran Alderborn

Göran Alderborn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
    Patent number: 11975105
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 7, 2024
    Assignee: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
  • MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS
    Publication number: 20200230063
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 23, 2020
    Applicant: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
  • Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
    Patent number: 10561617
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 18, 2020
    Assignee: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
  • MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS
    Publication number: 20170360715
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 21, 2017
    Applicant: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén